Serum proteomic analysis of a pre-symptomatic multiple sclerosis cohort

European Journal of Neurology

Volumn 22, Issue 3, 2015, Pages 591-599

  Wallin, M T ^a,b   Oh, U ^c   Nyalwidhe, J ^d   Semmes, J ^d   Kislinger, T ^e   Coffman, P ^a   Kurtzke, J F ^a,b   Jacobson, S ^f  

^a VA Multiple Sclerosis Center of Excellence East   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

^f NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Epidemiology; Multiple sclerosis; Proteomics

Indexed keywords

ALBUMIN; ALPHA 1 ACID GLYCOPROTEIN 2; ALPHA 1 ANTICHYMOTRYPSIN; APOLIPOPROTEIN B100; APOLIPOPROTEIN C1; APOLIPOPROTEIN C2; APOLIPOPROTEIN D; ATTRACTIN; BETA2 GLYCOPROTEIN 1; BIOTINIDASE; BLOOD CLOTTING FACTOR 10; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; COMPLEMENT FACTOR I; FIBRONECTIN; GLYCOPROTEIN; GLYCOSYLATED PROTEIN; HISTIDINE RICH GLYCOPROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA CHAIN; LEUCINE RICH ALPHA 2 GLYCOPROTEIN; OROSOMUCOID; PHOSPHATIDYLINOSITOL GLYCAN SPECIFIC PHOSPHOLIPASE D; PLASMINOGEN; PROTEOME; PROTHROMBIN; SERUM AMYLOID P; THYROXINE BINDING GLOBULIN; TRANSFERRIN; UNCLASSIFIED DRUG; ZINC ALPHA 2 GLYCOPROTEIN;

ADULT; ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; LIPID TRANSPORT; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; ONSET AGE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEOMICS; TANDEM MASS SPECTROMETRY; VETERAN; BLOOD; FOLLOW UP; PRODROMAL SYMPTOM; UNITED STATES;

ADULT; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MULTIPLE SCLEROSIS; PRODROMAL SYMPTOMS; PROTEOME; PROTEOMICS; UNITED STATES;

EID: 84922712898     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12534     Document Type: Article

References (20)

1. Farias AS, Pradella F, Schmitt A, Santos LM, Martins-de-Souza D. Ten years of proteomics in multiple sclerosis. Proteomics 2014; 14: 467-480.
2. Avasarala JR, Wall MR, Wolfe GM. A distinctive molecular signature of multiple sclerosis derived from MALDI-TOF/MS and serum proteomic pattern analysis: detection of three biomarkers. J Mol Neurosci 2005; 25: 119-125.
3. Teunissen C, Koel-Simmelink M, Pham T, et al. Identification of biomarkers for diagnosis and progression of MS by MALDI-TOF mass spectrometry. Mult Scler 2011; 17: 838-850.
4. Almeras L, Lefranc D, Drobecq H, et al. New antigenic candidates in multiple sclerosis: identification by serological proteome analysis. Proteomics 2004; 4: 2184-2194.
5. De Masi R, Vergara D, Pasca S, et al. PBMCs protein expression profile in relapsing IFN-treated multiple sclerosis: a pilot study on relation to clinical findings and brain atrophy. J Neuroimmunol 2009; 210: 80-86.
6. Liu J, Yin L, Dong H, et al. Decreased serum levels of nucleolin protein fragment, as analyzed by bead-based proteomic technology, in multiple sclerosis patients compared to controls. J Neuroimmunol 2012; 250: 71-76.
7. O'Connor KC, Roy SM, Becker CH, Hafler DA, Kantor AB. Comprehensive phenotyping in multiple sclerosis: discovery based proteomics and the current understanding of putative biomarkers. Dis Markers 2006; 22: 213-225.
8. Rithidech K, Honikel L, Milazzo M, Madigan D, Troxell R, Krupp L. Protein expression profiles in pediatric MS: potential biomarkers. Mult Scler 2009; 15: 455-464.
9. Wallin M, Page W, Kurtzke J. MS in US veterans of the Vietnam era and later military service: race, sex, and geography. Ann Neurol 2004; 55: 65-71.
10. Anderson NL, Polanski M, Pieper R, et al. The human plasma proteome: a non-redundant list developed by combination of four separate sources. Mol Cell Proteomics 2004; 3: 311-326.
11. Rengarajan K, de Smet MD, Wiggert B. Removal of albumin from multiple human serum samples. Biotechniques 1996; 20: 30-32.
12. Taylor P, Nielsen PA, Trelle MB, et al. Automated 2D peptide separation on a 1D nano-LC-MS system. J Proteome Res 2009; 8: 1610-1616.
13. Dumont D, Noben JP, Raus J, Stinissen P, Robben J. Proteomic analysis of cerebrospinal fluid from multiple sclerosis patients. Proteomics 2004; 4: 2117-2124.
14. Sobel R, Mitchell M. Fibronectin in MS lesions. Am J Pathol 1989; 135: 161-168.
15. Tokatli A, Coskun T, Ozalp I. Biotinidase deficiency with neurological features resembling multiple sclerosis. J Inherit Metab Dis 1997; 20: 707-708.
16. Liu S, Bai S, Qin Z, Yang Y, Cui Y, Qin Y. Quantitative proteomic analysis of the cerebrospinal fluid of patients with multiple sclerosis. J Cell Mol Med 2009 Aug; 13: 1586-1603.
17. Liu T, Donahue KC, Hu J, et al. Identification of differentially expressed proteins in experimental autoimmune encephalomyelitis by proteomic analysis of the spinal cord. J Proteome Res 2007; 6: 2565-2575.
18. Rosenling T, Stoop MP, Attali A, et al. Profiling and identification of cerebrospinal fluid proteins in a rat EAE model of multiple sclerosis. J Proteome Res 2012; 11: 2048-2060.
19. Linker RA, Brechlin P, Jesse S, et al. Proteome profiling in murine models of multiple sclerosis: identification of stage specific markers and culprits for tissue damage. PLoS ONE 2009; 4: e7624.
20. Miljkovic D, Spasojevic I. Multiple sclerosis: molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal 2013; 19: 2286-2334.